Media Summary: The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation described content and format requirements for composition statements of drug products and explained what to ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ...
Agdd 2024 D1s09 Q A - Detailed Analysis & Overview
The second of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. This presentation described content and format requirements for composition statements of drug products and explained what to ... This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... The second of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. FDA experts demonstrate the FDA's Generic Drug User Fee Amendments (GDUFA) Science and Research Program's ... The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.
This presentation explained factors that could impact first-cycle bioequivalence (BE) adequacy based on observed BE ... This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ... This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ... This presentation identified recent product-specific guidance (PSG) documents that include detailed language regarding the use ... Closing remarks from day one of the Advancing Generic Drug Development Conference delivered by Dr. Sau (Larry) Lee. This presentation discussed the ANDA landscape for topical products applied to the skin and identified challenges associated ...
